These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 9553809)

  • 21. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis.
    Shiina H; Igawa M; Shigeno K; Yamasaki Y; Urakami S; Yoneda T; Wada Y; Honda S; Nagasaki M
    Oncology; 1999 Apr; 56(3):239-47. PubMed ID: 10202280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. p53 and MDM2 immunostaining in pulmonary blastomas and bronchogenic carcinomas.
    Pacinda SJ; Ledet SC; Gondo MM; Langston C; Brown RW; Carmona PA; Franklin RB; Roggli VL; Cagle PT
    Hum Pathol; 1996 Jun; 27(6):542-6. PubMed ID: 8666362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes.
    Pfister C; Larue H; Moore L; Lacombe L; Veilleux C; Tetu B; Meyer F; Fradet Y
    Int J Cancer; 2000 Jan; 89(1):100-4. PubMed ID: 10719738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistochemical comparison of uterine papillary serous and papillary endometrioid carcinoma: clues to pathogenesis.
    Demopoulos RI; Mesia AF; Mittal K; Vamvakas E
    Int J Gynecol Pathol; 1999 Jul; 18(3):233-7. PubMed ID: 12092593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
    Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
    Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level.
    Alkushi A; Lim P; Coldman A; Huntsman D; Miller D; Gilks CB
    Int J Gynecol Pathol; 2004 Apr; 23(2):129-37. PubMed ID: 15084841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical status of p53, MDM2, bcl2, bax, and ER in invasive ductal breast carcinoma in Tunisian patients.
    Baccouche S; Daoud J; Frikha M; Mokdad-Gargouri R; Gargouri A; Jlidi R
    Ann N Y Acad Sci; 2003 Dec; 1010():752-63. PubMed ID: 15033823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunoreactivity for p53 and mdm2 and the detection of p53 mutations in human malignant mesothelioma.
    Segers K; Backhovens H; Singh SK; De Voecht J; Ramael M; Van Broeckhoven C; Van Marck E
    Virchows Arch; 1995; 427(4):431-6. PubMed ID: 8548129
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The combination of p53 and age predict cancer specific death in advanced stage (FIGO Ic-IV) of endometrial carcinoma of endometrioid type. An immunohistochemical examination of growth fraction: Ki-67, MIB-1 and PC10; suppressor oncogene protein: p53; oncogene protein: p185 and age, hormone treatment, stage, and histologic grade.
    Nielsen AL; Nyholm HC
    Eur J Obstet Gynecol Reprod Biol; 1996 Dec; 70(1):79-85. PubMed ID: 9031925
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases.
    Darvishian F; Hummer AJ; Thaler HT; Bhargava R; Linkov I; Asher M; Soslow RA
    Am J Surg Pathol; 2004 Dec; 28(12):1568-78. PubMed ID: 15577675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunohistochemical analysis of p53 protein over-expression in endometrial carcinomas: inverse correlation with sex steroid receptor status.
    Koshiyama M; Konishi I; Wang DP; Mandai M; Komatsu T; Yamamoto S; Nanbu K; Naito MF; Mori T
    Virchows Arch A Pathol Anat Histopathol; 1993; 423(4):265-71. PubMed ID: 8236823
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistochemical status of p53, mdm2 and Ki-67 in malignant fibrous histiocytoma.
    Szadowska A; Olborski B; Harezga-Bal B; Debiec-Rychter M
    Pol J Pathol; 1998; 49(1):15-21. PubMed ID: 9640970
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of P53, MDM2 and Ki-67 antigens in soft tissue sarcomas.
    Szadowska A; Olborski B; Harezga-Bal B; Debiec-Rychter M
    Pol J Pathol; 1999; 50(1):9-16. PubMed ID: 10412269
    [TBL] [Abstract][Full Text] [Related]  

  • 34. P53/MDM2 overexpression in metastatic endometrial cancer: correlation with clinicopathological features and patient outcome.
    Jeczen R; Skomra D; Cybulski M; Schneider-Stock R; Szewczuk W; Roessner A; Rechberger T; Semczuk A
    Clin Exp Metastasis; 2007; 24(7):503-11. PubMed ID: 17671841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunohistochemical and molecular analysis of p53, MDM2, proliferating cell nuclear antigen and Ki67 in benign and malignant peripheral nerve sheath tumours.
    Kindblom LG; Ahldén M; Meis-Kindblom JM; Stenman G
    Virchows Arch; 1995; 427(1):19-26. PubMed ID: 7551341
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nuclear accumulation of MDM2 protein in well-differentiated papillary thyroid carcinomas.
    Jennings T; Bratslavsky G; Gerasimov G; Troshina K; Bronstein M; Dedov I; Alexandrova G; Figge J
    Exp Mol Pathol; 1995 Jun; 62(3):199-206. PubMed ID: 8612724
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
    Lax SF; Kurman RJ
    Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. P53 and Murine Double Mimute 2 (MDM2) Expression Changes and Significance in Different Types of Endometrial Lesions.
    Jiang Z; Xu W; Dan G; Liu Y; Xiong J
    Med Sci Monit; 2016 Dec; 22():4786-4793. PubMed ID: 27924072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
    Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M
    Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical significance of p53, mdm2, and bcl-2 proteins in renal cell carcinoma.
    Uchida T; Gao JP; Wang C; Jiang SX; Muramoto M; Satoh T; Minei S; Shimura S; Irie A; Kameya T; Baba S
    Urology; 2002 Apr; 59(4):615-20. PubMed ID: 11927338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.